Bladder Urothelial Carcinoma Clinical Trial
Official title:
The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma
Bladder urothelial carcinoma (UC) is a common malignancy and the incidence is increasing by years in Taiwan. Chemoresistance was inevitable in treatment of metastatic disease and lead to the ominous outcomes. To develop novel therapeutic strategies to overcome chemoresistance is imperative. Cancer cells uptake glucose at higher rates than normal tissue but use most of glucose for glycolysis even under normoxia condition, which is known as the Warburg effect. Pyruvate kinase (PK) catalyzes the last step in the process of glycolysis, and one of it isoform--PKM2 has been reported to be associated with tumor progression and some specific tissues and promotes the Warburg effect in cancer cells.
Regulation of PKM2 can be a novel target of cancer therapy. Meanwhile, PKM2 may play a
critical role in the development of drug resistance and can be a promising target to
overcome drug resistance.
In this study, our specific aims are as follows:
1. To prove the differentia expression levels of PKM2 in UC cells and drug-resistant UC
cells, as well as in human UC tissues and drug-resistant UC tissues.
2. To examine the effect of PKM2 regulations（PKM2 siRNA and shikonin）on invasiveness and
metastatic ability of UC cells and clarify the role of PKM2 in human UC cells.
3. To investigate the combinatory effect of PKM2 regulations（PKM2 siRNA and shikonin）and
currently used chemotherapeutic agents (cisplatin，gemcitabine ,doxorubicin). Do PKM2
regulations enhance the cytotoxic effect of chemotherapy and overcome the
chemoresistance？
4. To further prove the in vitro findings in the nude mice xenograft model。
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03039413 -
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
|
Early Phase 1 | |
| Active, not recruiting |
NCT03601455 -
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
|
Phase 2 | |
| Completed |
NCT02989064 -
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
|
Phase 1 | |
| Terminated |
NCT00072137 -
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
|
Phase 1 | |
| Withdrawn |
NCT05564416 -
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
|
Phase 2 | |
| Recruiting |
NCT04570410 -
Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06167356 -
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
|
||
| Terminated |
NCT05052372 -
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
|
||
| Terminated |
NCT03266900 -
A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival
|
Early Phase 1 | |
| Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03473730 -
Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
|
Early Phase 1 | |
| Active, not recruiting |
NCT03138824 -
Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC
|
N/A | |
| Recruiting |
NCT05788484 -
A Study of CDX-585 in Patients With Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT04216290 -
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study)
|
Phase 2 | |
| Recruiting |
NCT06416319 -
Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct)
|
N/A | |
| Recruiting |
NCT03775265 -
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT06263153 -
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
|
Phase 2 | |
| Completed |
NCT00238420 -
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02496208 -
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
|
Phase 1 |